Interim report
Page 1
Summary of Consolidated Financial Results [ IFRS ] for the First Three Months of the Fiscal Year Ending March 31 , 2027 Listed company name Code Listed stock exchanges URL Company representative Contact Phone Scheduled date for dividend payment Preparation of supplementary material for quarterly earnings Holding of earnings announcement : Sysmex Corporation : 6869 : Tokyo Stock Exchange : August 7 , 2026 : www.sysmex.co.jp/en : Iwane Matsui , President Takuro Minami , Executive Vice President of Corporate Business Administration 078 ( 265 ) -0500 : : : Yes : Yes ( Unit : Millions of Yen ) 1. Results for the First Three Months of the Fiscal Year Ending March 31 , 2027 ( 1 ) Operating results ( % changes as compared with the corresponding period of the previous fiscal year ) Operating profit Net Sales Profit before tax Profit Three months 130,674 23.6 % 14,821 39.5 % 14,110 79.2 % 8,616 92.5 % ended Jun . 30 , 2026 Three months 105,731 ( 5.6 ) % 10,628 ( 36.5 ) % 7,873 ( 53.6 ) % 4,476 ( 59.2 ) % ended Jun . 30 , 2025 Profit attributable to owners of the parent Total comprehensive income Basic earnings per share ( Yen ) Diluted earnings per share ( Yen ) Three months 8,691 90.9 % 15,209 88.7 % 14.17 14.17 ended Jun . 30 , 2026 Three months 4,553 ( 58.7 ) % 8,059 ( 67.3 ) % 7.30 7.30 ended Jun . 30 , 2025 ( 2 ) Financial condition Total assets Total equity Equity attributable to owners of the parent Equity attributable to owners of the parent to total assets As of Jun . 30 , 2026 As of Mar. 31 , 2026 746,637 707,532 486,181 505,676 485,581 65.0 505,000 71.4 2. Dividend Dividend per share First quarter ( Yen ) Second quarter ( Yen ) Third quarter ( Yen ) Year - end ( Yen ) Annual ( Yen ) Year ended Mar. 31 , 2026 19.00 19.00 38.00 Year ending Mar. 31 , 2027 Year ending Mar. 31 , 2027 20.00 20.00 40.00 ( Forecast ) Note : Revision of dividends forecast for this period : No
Page 2
3. Financial Forecast for the Year Ending March 31, 2027 (% changes as compared with the corresponding period of the previous fiscal year) Net Sales Operating profit Profit before tax Profit attributable to owners of the parent Basic earnings per share (Yen) Six months ending Sep. 30, 2026 265,000 14.0% 25,000 (24.1)% 23,000 (23.2)% 15,000 (21.1)% 24.68 Year ending Mar. 31, 2027 545,000 9.0% 60,000 15.8% 56,000 14.2% 37,000 4.4% 60.89 Note: Revision of financial forecast for this period: Yes 4. Other Information (1) Significant changes in scope of consolidation: Yes Newly included: One company (Sysmex BioMajesty Co., Ltd ) (2) Changes in accounting policies and accounting estimates 1) Changes in accounting policies required by IFRS: No 2) Other changes in accounting policies: No 3) Changes in accounting estimates: No (3) Number of outstanding stock (common stock) 1) Number of outstanding stock at the end of each fiscal period (including treasury stock): 629,480,076 shares as of Jun. 30, 2026; 629,480,076 shares as of Mar. 31, 2026 2) Number of treasury stock at the end of each fiscal period: 24,275,357 shares as of Jun. 30, 2026; 7,995,365 shares as of Mar. 31, 2026 3) Average number of outstanding stock for each period (cumulative): 613,223,088 shares for the three months ended Jun. 30, 2026 623,604,502 shares for the three months ended Jun. 30, 2025 Note: The Company has introduced the Executive Compensation BIP Trust and the ESOP Trust. Company shares held by these trusts are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and th e average number of outstanding stock for the period. * Review of the accompanying quarterly consolidated financial statements by a certified public accountant or auditing firm: Yes * Explanation regarding the appropriate use of financial forecast and other information 1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to “3) Consolidated financial forecast” within “1. Qualitative information on quarterly financial results” on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts. 2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Friday, August 7, 2026.
Page 3
- 1 - Content of Supplementary Materials 1. Qualitative information on quarterly financial results 2 1) Operating performance analysis 2 2) Financial conditions analysis 3 3) Consolidated financial forecast 4 2. Condensed quarterly consolidated financial statements and notes 5 1) Condensed quarterly consolidated statement of financial position 5 2) Condensed quarterly consolidated statement of income 7 3) Condensed quarterly consolidated statement of comprehensive income 8 4) Condensed quarterly consolidated statement of changes in equity 9 5) Condensed quarterly consolidated statement of cash flows 10 6) Notes to the condensed quarterly consolidated financial statements 11 1. Key considerations on the basis for the preparation of condensed quarterly consolidated financial statements 11 2. Notes related to the going concern assumption 11 3. Segment information 11
Page 4
－ 2 － 1. Qualitative information on quarterly financial results Future-related information contained in the text below is based on the judgement as of the end of the fiscal period under review. 1) Operating performance analysis The Group's consolidated financial results for the first quarter of the fiscal year ending March 31, 2027 are as follows. Net sales by destination Three months ended June 30, 2025 Three months ended June 30, 2026 YoY (Previous period = 100) Amount (Millions of yen) Percentage of total (%) Amount (Millions of yen) Percentage of total (%) Japan 11,011 10.4 17,391 13.3 157.9 Americas 30,205 28.6 41,966 32.1 138.9 EMEA (Europe, the Middle East, and Africa) 35,151 33.2 44,125 33.8 125.5 China 17,272 16.4 13,388 10.2 77.5 AP (Asia Pacific) 12,090 11.4 13,803 10.6 114.2 Overseas subtotal 94,720 89.6 113,283 86.7 119.6 Total 105,731 100.0 130,674 100.0 123.6 In Japan, sales in the clinical chemistry field increased following the start of business operations by Sysmex BioMajesty Co., Ltd., acquired from JEOL Ltd. As a result, sales in Japan up 57.9% year on year, to ¥17,391 million. The ratio of sales in Japan increased 2.9 percentage points, to 13.3%. Overseas, sales of hematology instruments, reagents, and maintenance services increased. This factor, coupled with depreciation of the yen in foreign exchange markets, caused overseas sales to up 19.6%, to ¥113,283 million. The overseas sales ratio down 2.9 percentage points, to 86.7%. Selling, general and administrative (SG&A) expenses totaled ¥42,613 million, up 11.3% year on year, mainly due to increases in personnel accompanying the expansion of business. R&D expenses came to ¥7,211 million, up 12.5%. As a result, on a consolidated basis for the first quarter of the fiscal year ending March 31, 202 7, net sales amounted to ¥130,674 million (up 23.6% year on year), operating profit was ¥14,821 million (up 39.5%), profit before tax was ¥14,110 million (up 79.2%), and profit attributable to owners of the parent totaled ¥8,691 million (up 90.9%). Performance by segment (1) Headquarters In Japan, sales in the clinical chemistry field increased following the start of business operations by Sysmex BioMajesty Co., Ltd. In addition, sales of reagents and maintenance services in the hematology field rose in South Korea. As a result, segment sales rose 49.6% year on year, to ¥25,427 million. On the profit front, higher net sales led to an increase in gross profit, bolstering segment profit (operating profit) 189.1% year on year, to ¥6,437 million.
Page 5
－ 3 － (2) Americas RHQ In North America, sales of instruments, reagents and maintenance services in the hematology field increased. In Central and South America, sales of hematology instruments and reagents increased, as did sales of urinalysis reagents. As a result, segment sales rose 37.2% year on year, to ¥39,211 million. On the profit front, although SG&A expenses increased, higher net sales and an improvement in the cost of sales ratio pushed up segment profit (operating profit) 223.7% year on year, to ¥2,593 million. (3) EMEA RHQ Sales of instruments and reagents in the hematology, hemostasis and urinalysis fields increased, mainly in European countries. As a result, segment sales rose 24.7% year on year, to ¥42,378 million. On the profit front, although SG&A expenses increased, but the higher gross profit on increased sales boosted segment profit (operating profit) 63.7% year on year, to ¥3,705 million. (4) China RHQ Sales of instruments, reagents and maintenance services in the hemostasis field decreased, as did sales of instruments in the hematology field. As a result, segment sales fell 22.6% year on year, to ¥13,343 million. On the profit front, although SG&A expenses decreased, lower sales caused gross profit to decline. Consequently, segment profit (operating profit) fell 42.9% year on year, to ¥954 million. (5) AP RHQ Sales of reagents in the hematology and hemostasis fields increased, mainly in the Indian market. As a result, segment sales rose 15.5% year on year, to ¥10,313 million. On the profit front, despite higher net sales, a deterioration in the cost of sales ratio and an increase in SG&A expenses caused segment profit (operating profit) to fall 31.0% year on year, to ¥1,059 million. 2) Financial conditions analysis (1) Financial conditions As of June 30, 2026, total assets amounted to ¥746,637 million, a increase of ¥39,105 million compared with March 31, 2026. This increase was due chiefly to rises of ¥29,517 million in cash and cash equivalents and ¥11,221 million in inventories. Total liabilities increased by ¥58,599 million from March 31, 2026, to ¥260,455 million. This rise was mainly because of a ¥49,821 million increase in long-term loans payable. Total equity decreased by ¥19,494 million from March 31, 2026, to ¥486,181 million. This was mainly owing to a decrease of ¥22,865 million resulting from the acquisition of treasury stock. As a result, the equity attributable to owners of the parent to total assets down 6.4 percentage points, from 71.4% as of March 31, 2026, to 65.0%. (2) Cash flows As of June 30, 2026, cash and cash equivalents amounted to ¥113,634 million, up ¥29,517 million from March 31, 2026. Cash flows from various activities during the first quarter are described in more detail below. (Cash flows from operating activities) Net cash provided by operating activities was ¥35,595 million (up ¥26,103 million from the first three months of the previous fiscal year). This was due mainly to profit before tax of ¥14,110 million (up ¥6,237 million year on year), depreciation and amortization of ¥12,028 million (up ¥1,265 million), a decrease in trade receivables of ¥17,687 million (down ¥1,434 million), and a decrease in accrued bonuses of ¥7,431 million (down ¥583 million). (Cash flows from investing activities) Net cash used in investing activities was ¥18,595 million (up ¥6,492 million). This was attributable chiefly to purchases of property, plant and equipment of ¥6,314 million (up ¥623 million year on year), purchases of intangible assets of ¥3,771 million (down ¥2,656 million), and acquisitions of subsidiaries or other businesses of ¥7,838 million (up ¥7,838 million).
Page 6
－ 4 － (Cash flows from financing activities) Net cash provided by financing activities was ¥12,032 million (¥13,301 million used in the previous period). This was due mainly to proceeds from long-term loans payable of ¥50,000 million (up ¥50,000 million year on year), purchases of treasury shares of ¥22,883 million (up ¥22,883 million), and dividends paid of ¥11,808 million (up ¥1,207 million). 3) Consolidated financial forecast For the Company's consolidated financial forecasts for the Six Months Ended September 30, 2026 and the full fiscal year, please refer to Announcement Regarding Revi sion of Financial Forecast for the Six Months Ending September 30, 2026, and Revision of Full -Year Financial Forecast for the Fiscal Year Ending March 31, 2027, announced today (August 7, 2026).
Page 7
－ 5 － 2. Condensed quarterly consolidated financial statements and notes 1) Condensed quarterly consolidated statement of financial position (Unit: Millions of yen) As of March 31, 2026 As of June 30, 2026 Assets Current assets Cash and cash equivalents 84,117 113,634 Trade and other receivables 168,783 158,791 Inventories 95,613 106,835 Other short-term financial assets 775 635 Income taxes receivable 8,757 5,973 Other current assets 30,559 30,494 Total current assets 388,606 416,365 Non-current assets Property, plant and equipment 150,396 154,448 Goodwill 4,138 8,730 Intangible assets 93,173 92,659 Investments accounted for using the equity method 150 454 Trade and other receivables 34,756 36,979 Other long-term financial assets 14,025 14,654 Asset for retirement benefits 0 30 Other non-current assets 6,643 6,509 Deferred tax assets 15,641 15,804 Total non-current assets 318,925 330,272 Total assets 707,532 746,637
Page 8
－ 6 － (Unit: Millions of yen) As of March 31, 2026 As of June 30, 2026 Liabilities and equity Liabilities Current liabilities Trade and other payables 34,116 32,991 Lease liabilities 9,555 10,176 Other current financial liabilities 1,316 6,201 Income taxes payable 2,980 3,238 Provisions 1,342 1,446 Contract liabilities 20,770 20,045 Accrued expenses 22,610 27,837 Accrued bonuses 14,976 7,829 Other current liabilities 11,591 12,802 Total current liabilities 119,259 122,568 Non-current liabilities Long-term loans payable 31,646 81,468 Lease liabilities 29,280 31,881 Other non-current financial liabilities 35 30 Liability for retirement benefits 2,238 3,078 Provisions 1,307 1,316 Other non-current liabilities 12,198 13,729 Deferred tax liabilities 5,889 6,382 Total non-current liabilities 82,596 137,887 Total liabilities 201,856 260,455 Equity Equity attributable to owners of the parent Capital stock 14,898 14,898 Capital surplus 21,114 21,084 Retained earnings 416,253 413,136 Treasury stock (15,501) (38,366) Other components of equity 68,236 74,829 Total equity attributable to owners of the parent 505,000 485,581 Non-controlling interests 675 599 Total equity 505,676 486,181 Total liabilities and equity 707,532 746,637
Page 9
－ 7 － 2) Condensed quarterly consolidated statement of income (Unit: Millions of yen) Three months ended June 30, 2025 Three months ended June 30, 2026 Net sales 105,731 130,674 Cost of sales 51,267 64,364 Gross profit 54,463 66,310 Selling, general and administrative expenses 38,296 42,613 Research and development expenses 6,407 7,211 Other operating income 1,084 1,064 Other operating expenses 215 2,728 Operating profit 10,628 14,821 Financial income 198 245 Financial expenses 909 1,272 Share of profit (loss) of associates accounted for using the equity method (534) (477) Foreign exchange gain (loss) (1,508) 793 Profit before tax 7,873 14,110 Income taxes expenses 3,397 5,494 Profit 4,476 8,616 Profit attributable to Owners of the parent 4,553 8,691 Non-controlling interests (76) (75) Profit 4,476 8,616 (Unit: Yen) Earnings per share Basic 7.30 14.17 Diluted 7.30 14.17
Page 10
－ 8 － 3) Condensed quarterly consolidated statement of comprehensive income (Unit: Millions of yen) Three months ended June 30, 2025 Three months ended June 30, 2026 Profit 4,476 8,616 Other comprehensive income Items that will not be reclassified subsequently to profit or loss Net gain (loss) on financial assets measured at fair value through other comprehensive income 154 6 Total 154 6 Items that may be reclassified subsequently to profit or loss Exchange differences on translation of foreign operations 3,422 6,580 Share of other comprehensive income of investments accounted for using the equity method 5 6 Total 3,428 6,586 Total other comprehensive income 3,582 6,592 Comprehensive income 8,059 15,209 Comprehensive income attributable to Owners of the parent 8,135 15,284 Non-controlling interests (76) (75) Comprehensive income 8,059 15,209
Page 11
－ 9 － 4) Condensed quarterly consolidated statement of changes in equity Three months ended June 30, 2025 (Unit: Millions of yen) Equity attributable to owners of the parent Non- controlling interests Total equity Capital stock Capital surplus Retained earnings Treasury stock Other components of equity Total As of April 1, 2025 14,887 20,960 402,820 (12,318) 37,425 463,776 758 464,534 Profit 4,553 4,553 (76) 4,476 Other comprehensive income 3,582 3,582 3,582 Comprehensive income － － 4,553 － 3,582 8,135 (76) 8,059 Exercise of warrants 10 6 16 16 Share-based payment transactions 13 13 13 Cash dividends (10,601) (10,601) (10,601) Purchase of treasury stock － － Disposal of treasury stock (9) 9 － － Transfer to retained earnings (41) 41 － － Total transactions with the owners 10 9 (10,642) 9 41 (10,571) － (10,571) As of June 30, 2025 14,898 20,970 396,731 (12,309) 41,050 461,340 681 462,022 Three months ended June 30, 2026 (Unit: Millions of yen) Equity attributable to owners of the parent Non- controlling interests Total equity Capital stock Capital surplus Retained earnings Treasury stock Other compone nts of equity Total As of April 1, 2026 14,898 21,114 416,253 (15,501) 68,236 505,000 675 505,676 Profit 8,691 8,691 (75) 8,616 Other comprehensive income 6,592 6,592 6,592 Comprehensive income － － 8,691 － 6,592 15,284 (75) 15,209 Exercise of warrants － － Share-based payment transactions (20) (20) (20) Cash dividends (11,808) (11,808) (11,808) Purchase of treasury stock (22,883) (22,883) (22,883) Disposal of treasury stock (8) 18 9 9 Transfer to retained earnings － － Total transactions with the owners － (29) (11,808) (22,865) － (34,703) － (34,703) As of June 30, 2026 14,898 21,084 413,136 (38,366) 74,829 485,581 599 486,181
Page 12
－ 10 － 5) Condensed quarterly consolidated statement of cash flows (Unit: Millions of yen) Three months ended June 30, 2025 Three months ended June 30, 2026 Cash flows from operating activities Profit before tax 7,873 14,110 Depreciation and amortization 10,762 12,028 Share of loss (profit) of associates accounted for using the equity method 534 477 Loss on retirement of non-current assets 57 148 Decrease (increase) in trade receivable 19,122 17,687 Decrease (increase) in advance payments (794) (1,167) Decrease (increase) in inventories (4,757) (4,707) Increase (decrease) in trade payable (2,016) (765) Increase (decrease) in accounts payable–other (608) 293 Increase (decrease) in contract liabilities (937) (776) Increase (decrease) in accrued expenses (827) 4,686 Decrease/increase in consumption taxes receivable/payable 1,898 4,755 Increase (decrease) in accrued bonuses (8,014) (7,431) Other－net (784) (1,898) Subtotal 21,507 37,440 Interest and dividend received 168 252 Interest paid (540) (574) Income taxes paid (11,643) (1,523) Net cash provided by (used in) operating activities 9,492 35,595 Cash flows from investing activities Purchases of property, plant and equipment (5,691) (6,314) Purchases of intangible assets (6,427) (3,771) Payments resulting in an increase in long-term prepaid expenses (165) (18) Payments into time deposits (19) (0) Proceeds from withdrawal of time deposits 434 239 Purchase of other financial assets (49) (261) Acquisition of investments accounted for using the equity method － (350) Acquisitions of subsidiaries or other businesses － (7,838) Other－net (182) (280) Net cash provided by (used in) investing activities (12,102) (18,595) Cash flows from financing activities Proceeds from long-term loans payable － 50,000 Repayments of long-term loans payable (178) (178) Exercise of warrants 16 － Purchase of treasury shares － (22,883) Dividends paid (10,601) (11,808) Repayments of lease liabilities (2,547) (3,107) Other－net 9 9 Net cash provided by (used in) financing activities (13,301) 12,032 Effects of exchange rate changes on cash and cash equivalents 817 485 Net increase (decrease) in cash and cash equivalents (15,094) 29,517 Cash and cash equivalents at the beginning of the term 89,570 84,117 Cash and cash equivalents at the end of the term 74,476 113,634
Page 13
－ 11 － 6) Notes to the condensed quarterly consolidated financial statements 1. Key considerations on the basis for the preparation of condensed quarterly consolidated financial statements The condensed quarterly consolidated financial statements have been prepared in accordance with Article 5, Paragraph 2 of the Standards for Preparation of Quarterly Consolidated Financial Statements, etc. of Tokyo Stock Exchange, Inc. (However, in accordan ce with Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements, some disclosures in International Accounting Standard No. 34 “Interim Financial Reporting” are omitted.) 2. Notes related to the going concern assumption Not applicable 3. Segment information 1) Overview of reportable segments The reportable segments of the Company and its subsidiaries (the Group) are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations. The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan and East Asia by Sysmex and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established therein. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Some overseas subsidiaries are managed by Sysmex depending on the nature of their business. The five managing company-specific segments are “Headquarters,” “Americas RHQ,” “EMEA RHQ,” “China RHQ,” and “AP RHQ.” The companies included in these reportable segments are outlined below. Reportable segments Companies included in the reportable segments Headquarters Sysmex Corporation, Sysmex RA Co., Ltd., 13 other domestic subsidiaries, Oxford Gene Technology IP Limited, Sysmex Partec GmbH, Sysmex Korea Co., Ltd., 11 other overseas subsidiaries Americas RHQ Sysmex America, Inc., Sysmex Reagents America, Inc., Sysmex do Brasil Industria e Comercio Ltda., five other subsidiaries in the Americas EMEA RHQ Sysmex Europe SE, Sysmex Deutschland GmbH, Sysmex UK Limited, Sysmex France S.A.S., 25 other subsidiaries in the EMEA region China RHQ Sysmex Shanghai ltd., Jinan Sysmex Medical Electronics Co., Ltd., two other subsidiaries in China AP RHQ Sysmex Asia Pacific Pte Ltd., Sysmex India Pvt. Ltd., nine other subsidiaries in the Asia Pacific region 2) Segment profit and operating results Profit and operating results from continuing operations by reportable segment of the Group are as follows; Intersegment sales are determined based on market prices or costs of goods manufactured. Accounting policies of reporting segments are consistent with the Group’s accounting policies indicated in the consolidated financial statements for the previous fiscal year.
Page 14
－ 12 － Three months ended June 30, 2025 (Unit: Millions of yen) Reportable segment Adjustments (Note 1) Consolidated (Note 2) Head- quarters Americas RHQ EMEA RHQ China RHQ AP RHQ Total Sales Sales to external customers 17,001 28,579 33,982 17,235 8,931 105,731 － 105,731 Intersegment sales 26,712 8 109 48 10 26,889 (26,889) － Total 43,713 28,588 34,092 17,283 8,942 132,620 (26,889) 105,731 Segment profit (loss) 2,227 801 2,263 1,672 1,535 8,499 2,129 10,628 Financial income － － － － － － － 198 Financial expenses － － － － － － － 909 Share of profit (loss) of associates accounted for using the equity method － － － － － － － (534) Foreign exchange gain (loss) － － － － － － － (1,508) Profit before tax － － － － － － － 7,873 Income taxes expenses － － － － － － － 3,397 Profit － － － － － － － 4,476 Notes: 1. Segment profit (loss) adjustments of ¥2,129 million include ¥2,222 million for the unrealized gains on inventories and negative ¥93 million for the unrealized gains on non-current assets. 2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.
Page 15
－ 13 － Three months ended June 30, 2026 (Unit: Millions of yen) Reportable segment Adjustments (Note 1) Consolidated (Note 2) Head- quarters Americas RHQ EMEA RHQ China RHQ AP RHQ Total Sales Sales to external customers 25,427 39,211 42,378 13,343 10,313 130,674 － 130,674 Intersegment sales 27,150 2 222 98 11 27,485 (27,485) － Total 52,577 39,214 42,601 13,442 10,325 158,160 (27,485) 130,674 Segment profit (loss) 6,437 2,593 3,705 954 1,059 14,750 71 14,821 Financial income － － － － － － － 245 Financial expenses － － － － － － － 1,272 Share of profit (loss) of associates accounted for using the equity method － － － － － － － (477) Foreign exchange gain (loss) － － － － － － － 793 Profit before tax － － － － － － － 14,110 Income taxes expenses － － － － － － － 5,494 Profit － － － － － － － 8,616 Notes: 1. Segment profit (loss) adjustments of ¥71 million include ¥628 million for the unrealized gains on inventories and negative ¥557 million for the unrealized gains on non-current assets. 2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.